These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

100 related articles for article (PubMed ID: 21137179)

  • 1. [Rivaroxaban and factor Xa inhibitors in clinical practice].
    Penka M
    Vnitr Lek; 2010 Sep; 56(9):920-6. PubMed ID: 21137179
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Rivaroxaban: a new oral factor Xa inhibitor.
    Perzborn E; Roehrig S; Straub A; Kubitza D; Mueck W; Laux V
    Arterioscler Thromb Vasc Biol; 2010 Mar; 30(3):376-81. PubMed ID: 20139357
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Rivaroxaban: mode of action].
    Drouet L
    Ann Fr Anesth Reanim; 2008 Dec; 27 Suppl 3():S9-15. PubMed ID: 19185786
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prevention and treatment of experimental thrombosis in rabbits with rivaroxaban (BAY 597939)--an oral, direct factor Xa inhibitor.
    Biemond BJ; Perzborn E; Friederich PW; Levi M; Buetehorn U; Büller HR
    Thromb Haemost; 2007 Mar; 97(3):471-7. PubMed ID: 17334516
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rivaroxaban. A novel, oral, direct factor Xa inhibitor in clinical development for the prevention and treatment of thromboembolic disorders.
    Perzborn E; Kubitza D; Misselwitz F
    Hamostaseologie; 2007 Sep; 27(4):282-9. PubMed ID: 17938768
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Orally administered factor xa inhibitor, rivaroxaban: a novel thromboembolic prophylaxis agent.
    Komotar RJ; Starke RM; Connolly ES
    Neurosurgery; 2008 Oct; 63(4):N10-1. PubMed ID: 18981864
    [No Abstract]   [Full Text] [Related]  

  • 7. Treatment of proximal deep-vein thrombosis with the oral direct factor Xa inhibitor rivaroxaban (BAY 59-7939): the ODIXa-DVT (Oral Direct Factor Xa Inhibitor BAY 59-7939 in Patients With Acute Symptomatic Deep-Vein Thrombosis) study.
    Agnelli G; Gallus A; Goldhaber SZ; Haas S; Huisman MV; Hull RD; Kakkar AK; Misselwitz F; Schellong S;
    Circulation; 2007 Jul; 116(2):180-7. PubMed ID: 17576867
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Assessment of laboratory assays to measure rivaroxaban--an oral, direct factor Xa inhibitor.
    Samama MM; Martinoli JL; LeFlem L; Guinet C; Plu-Bureau G; Depasse F; Perzborn E
    Thromb Haemost; 2010 Apr; 103(4):815-25. PubMed ID: 20135059
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A once-daily, oral, direct Factor Xa inhibitor, rivaroxaban (BAY 59-7939), for thromboprophylaxis after total hip replacement.
    Eriksson BI; Borris LC; Dahl OE; Haas S; Huisman MV; Kakkar AK; Muehlhofer E; Dierig C; Misselwitz F; Kälebo P;
    Circulation; 2006 Nov; 114(22):2374-81. PubMed ID: 17116766
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Oral, direct factor Xa inhibitors in development for the prevention and treatment of thromboembolic diseases.
    Turpie AG
    Arterioscler Thromb Vasc Biol; 2007 Jun; 27(6):1238-47. PubMed ID: 17379841
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Summary and perspectives. Rivaroxaban].
    Albaladejo P
    Ann Fr Anesth Reanim; 2008 Dec; 27 Suppl 3():S28-31. PubMed ID: 19185785
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rivaroxaban-once daily, oral, direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and Embolism Trial in Atrial Fibrillation: rationale and design of the ROCKET AF study.
    ROCKET AF Study Investigators
    Am Heart J; 2010 Mar; 159(3):340-347.e1. PubMed ID: 20211293
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rivaroxaban for the prevention of venous thromboembolism following major orthopedic surgery: the RECORD trials.
    Ageno W
    Expert Rev Cardiovasc Ther; 2009 Jun; 7(6):569-76. PubMed ID: 19505271
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Survival of heparins, oral anticoagulants, and aspirin after the year 2010.
    Fareed J; Hoppensteadt DA; Fareed D; Demir M; Wahi R; Clarke M; Adiguzel C; Bick R
    Semin Thromb Hemost; 2008 Feb; 34(1):58-73. PubMed ID: 18393143
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Rivaroxaban (Xarelto): efficacy and safety].
    Rosencher N; Arnaout L; Chabbouh T; Bellamy L
    Ann Fr Anesth Reanim; 2008 Dec; 27 Suppl 3():S22-7. PubMed ID: 19185784
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An optimised, rapid chromogenic assay, specific for measuring direct factor Xa inhibitors (rivaroxaban) in plasma.
    Samama MM; Amiral J; Guinet C; Perzborn E; Depasse F
    Thromb Haemost; 2010 Nov; 104(5):1078-9. PubMed ID: 20806114
    [No Abstract]   [Full Text] [Related]  

  • 17. Safety, pharmacodynamics, and pharmacokinetics of single doses of BAY 59-7939, an oral, direct factor Xa inhibitor.
    Kubitza D; Becka M; Voith B; Zuehlsdorf M; Wensing G
    Clin Pharmacol Ther; 2005 Oct; 78(4):412-21. PubMed ID: 16198660
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rivaroxaban: a novel, oral, direct factor Xa inhibitor.
    Abrams PJ; Emerson CR
    Pharmacotherapy; 2009 Feb; 29(2):167-81. PubMed ID: 19170587
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dose-escalation study of rivaroxaban (BAY 59-7939)--an oral, direct Factor Xa inhibitor--for the prevention of venous thromboembolism in patients undergoing total hip replacement.
    Eriksson BI; Borris LC; Dahl OE; Haas S; Huisman MV; Kakkar AK; Misselwitz F; Muehlhofer E; Kälebo P
    Thromb Res; 2007; 120(5):685-93. PubMed ID: 17292948
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Prophylaxis of thrombembolic diseases with rivaroxaban].
    Gassanov N; Caglayan E; Erdmann E; Er F
    Dtsch Med Wochenschr; 2010 Nov; 135(44):2189-92. PubMed ID: 20979005
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.